SEC Filing Summary: Athira Pharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. on August 16, 2021. The filing serves as a current report to announce the issuance of a press release detailing the Company's financial results for the quarter ended June 30, 2021. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in Bothell, WA.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were released via a press release (Exhibit 99.1), but the specific financial data points are not embedded within the body of this 8-K form.
Material Changes and Guidance
As the specific financial figures are not included in this text, no material changes versus prior periods, specific guidance, or management commentary on financial performance can be summarized from this document alone. The filing notes that the Company communicates material information through various channels, including its website and social media accounts (Twitter, LinkedIn, Facebook).
Investor Verification Checklist
- Review Exhibit 99.1 (the press release dated August 16, 2021) to obtain actual revenue, net loss, and cash position figures for the quarter ended June 30, 2021.
- Verify the Company's status as an Emerging Growth Company and any associated accounting standard elections.
- Check the Company's investor relations website and social media channels for additional context on product candidates and operational updates referenced in the filing.
- Confirm the trading symbol ATHA on The Nasdaq Global Select Market.